Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial

Abstract Background Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with loss of lung function and poor outcomes for patients. However, there are limited data on the time course of changes in forced expiratory volume in 1 s (FEV1) preceding the first reported symptom and after the start of an exacerbation. Methods WISDOM was a multinational, randomized, double-blind, active-controlled, 52-week study in patients with severe-to-very severe COPD. Patients received triple therapy (long-acting muscarinic antagonist and long-acting β2-agonist/inhaled corticosteroid [ICS]) for 6 weeks, and were randomized to continue triple therapy or stepwise withdrawal of the ICS (dual bronchodilator group). After suitable training, patients performed daily spirometry at home using a portable, battery-operated spirometer. In the present post hoc analysis, patients who continued to perform daily home spirometry and completed at least one measurement per week for a 56-day period before and after the start of a moderate or severe exacerbation were included. Missing values were imputed by linear interpolation (intermittent), backfilling (beginning) or carry forward (end). Exacerbation onset was the first day of a reported symptom of exacerbation. Results Eight hundred and eighty-eight patients in the WISDOM study had a moderate/severe exacerbation after the complete ICS withdrawal visit; 360 of them contributed at least one FEV1 measure per week for the 8 weeks before and after the event and are included in this analysis. Mean daily FEV1 began to decline from approximately 2 weeks before the onset of symptoms of an exacerbation, dropping from 0.907 L (mean Days − 56 to − 36 before the exacerbation) to 0.860 L on the first day of the exacerbation. After the exacerbation, mean FEV1 improved but did not return to pre-exacerbation levels (mean Days 36–56 after the exacerbation, 0.875 L). The pattern of FEV1 changes around exacerbations was similar in the triple therapy and dual bronchodilator groups, and a similar pattern was seen in moderate and severe exacerbations when analysed separately. Conclusions Mean lung function starts to decline prior to the first reported symptoms of an exacerbation, and does not recover to pre-exacerbation levels 8 weeks after the event. Trial registration WISDOM (ClinicalTrials.gov number, NCT00975195 ).

Tags
Data and Resources
To access the resources you must log in

This item has no data

Identity

Description: The Identity category includes attributes that support the identification of the resource.

Field Value
PID https://www.doi.org/10.6084/m9.figshare.c.4335614.v1
PID https://www.doi.org/10.15496/publikation-31121
URL http://dx.doi.org/10.6084/m9.figshare.c.4335614.v1
URL http://dx.doi.org/10.15496/publikation-31121
Access Modality

Description: The Access Modality category includes attributes that report the modality of exploitation of the resource.

Field Value
Access Right Closed Access
Attribution

Description: Authorships and contributors

Field Value
Author Watz, Henrik
Author Tetzlaff, Kay
Author Magnussen, Helgo
Author Mueller, Achim
Author Rodriguez-Roisin, Roberto
Author Wouters, Emiel
Author Vogelmeier, Claus
Author Calverley, Peter
Contributor University, My
Publishing

Description: Attributes about the publishing venue (e.g. journal) and deposit location (e.g. repository)

Field Value
Collected From Datacite
Hosted By figshare
Publication Date 2018-01-01
Publisher Figshare
Additional Info
Field Value
Language UNKNOWN
Resource Type Collection; Other ORP type
keyword FOS: Biological sciences
keyword FOS: Health sciences
system:type other
Management Info
Field Value
Source https://science-innovation-policy.openaire.eu/search/other?orpId=dedup_wf_001::437e886f95462bd3debd4ac08d7eb2e4
Author jsonws_user
Last Updated 20 December 2020, 02:31 (CET)
Created 20 December 2020, 02:31 (CET)